Tous Actualités
Suivre
Abonner Deutsche Effecten- und Wechsel-Beteiligungsges. AG

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: DEWB Investment Holding NOXXON Confirms Total Capital Raise of EUR35m

Berlin, Germany, 12 October 2010 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information
NOXXON Pharma AG
(website) announced today that in addition to the financing of EUR33m
which was recently announced on 27 May 2010 (see press release), it 
has concluded a further capital raise of EUR2m which brings the total
amount raised in this series D financing to EUR35m in aggregate.
The new investors who elected to participate in this financing round include CD
Ventures and other private investors.
Iain Buchanan, CEO of NOXXON Pharma AG, commented: "We are pleased to welcome
new investors to NOXXON´s shareholder base and to conclude this enhanced round
of financing. The company is poised to enter a new phase in its growth as the
main assets progress in clinical development. Maintaining a strong balance sheet
is essential as we look to build value."
General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email:  edelabre@noxxon.com
Website: http://www.noxxon.com
About NOXXON NOXXON Pharma AG is a biotechnology company developing a
promising new class of therapeutics called Spiegelmers, which are 
oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers can
be engineered to bind specifically to a precisely defined biological 
target and have been shown to be potent inhibitors. Clinical and 
pre-clinical studies of Spiegelmers to date have shown them to be 
exceptionally safe, well-tolerated, biologically stable and 
non-immunogenic. NOXXON has three programs in development, two of 
which have successfully completed their first Phase I clinical 
studies. The company has approximately 60 employees based at its 
headquarters in Berlin. NOXXON´s investors are NGN Capital, TVM 
Capital, Sofinnova Partners, Edmond de Rothschild Investment 
Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft 
(DEWB), Seventure Partners, The Dow Chemical Company, Dieckell Group,
Oppenheim Asset Management Services, IBG Risikokapitalfonds, VC Fonds
Berlin, CD Ventures and others.
About Spiegelmers® Spiegelmers® (L-stereoisomer RNA oligonucleotides)
are chemical entities based on synthetic mirror-image 
oligonucleotides which are highly selective for their pharmacological
target and potent inhibitors of target function. They combine the 
benefits of small molecule drugs and biopharmaceuticals. Due to their
unique mirror-image configuration Spiegelmers® are not metabolized 
and do not hybridize with native nucleic acids. Spiegelmers® also do 
not activate the innate immune response via toll-like receptors and 
showed an exceptionally favorable immunogenicity profile in 
pre-clinical testing.
end of announcement                               euro adhoc

Further inquiry note:

Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / Open Market / Entry Standard

Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Plus de actualités: Deutsche Effecten- und Wechsel-Beteiligungsges. AG